The NF-κB signaling pathway is constitutively active in activated B-cell-like (ABC) DLBCL as a result of oncogenic mutations in the Toll-like receptor (TLR) signaling pathway and the B-cell antigen receptor (BCR) signaling pathway [1–3]. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.